Table 5.
Functional enrichment analysis: canonical pathways
| Ingenuity canonical pathways | P value | Ratio | Molecules |
|---|---|---|---|
| Production of nitric oxide and reactive oxygen species in macrophages | 1.41E−05 | 0.05 | RHOG, APOB, PPP1R3C, RHOB, MAP3K8, IRS1, RBP4, CYBA, APOM, PIK3CG |
| LXR/RXR activation | 1.74E−05 | 0.07 | NCOR2, APOB, TF, VTN, RXRA, RBP4, PON3, APOM |
| FXR/RXR activation | 2.34E−05 | 0.06 | APOB, TF, VTN, RXRA, RBP4, NR5A2, PON3, APOM |
| RAR activation | 7.24E−05 | 0.05 | NCOR2, ADCY3, DUSP1, ZBTB16, RXRA, RBP4, ADCY9, NR2F2, PIK3CG |
| B cell receptor signaling | 4.27E−04 | 0.04 | INPP5D, PTK2B, EBF1, MAP3K8, IRS1, ETS1, RASSF5, PIK3CG |
| Type II diabetes mellitus signaling | 1.26E−03 | 0.05 | ACSL1, SLC2A2, IRS1, PKM, NSMAF, PIK3CG |
| Cardiac hypertrophy signaling | 1.66E−03 | 0.03 | RHOG, ADCY3, RHOB, MAP3K8, IRS1, CACNA1A, ADCY9, PIK3CG |
| Leptin signaling in obesity | 8.51E−03 | 0.05 | ADCY3, IRS1, ADCY9, PIK3CG |
| ERK/MAPK signaling | 1.10E−02 | 0.03 | PPP1R3C, DUSP1, PTK2B, IRS1, ETS1, PIK3CG |
| mTOR signaling | 1.12E−02 | 0.03 | RHOG, RPS6, RHOB, IRS1, RPS2, PIK3CG |
| VEGF signaling | 1.55E−02 | 0.04 | ACTG1, PTK2B, IRS1, PIK3CG |
| Maturity onset diabetes of young (MODY) signaling | 1.58E−02 | 0.10 | SLC2A2, CACNA1A |
| PPARα/RXRα activation | 2.63E−02 | 0.03 | NCOR2, ADCY3, RXRA, IRS1, ADCY9 |
| Atherosclerosis signaling | 3.09E−02 | 0.03 | APOB, ITGB2, RBP4, APOM |
| Adipogenesis pathway | 3.63E−02 | 0.03 | PLIN1, EBF1, NR2F2, HDAC7 |
| B cell development | 4.17E−02 | 0.06 | HLA-DOA, HLA-B |
| Insulin receptor signaling | 4.27E−02 | 0.03 | INPP5D, PPP1R3C, IRS1, PIK3CG |